Results 41 to 50 of about 403,362 (211)
The Journal of the National Comprehensive Cancer NetworkThe treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of ...
Shaji K. Kumar +35 more
semanticscholar +1 more source
Monaldi Archives for Chest Disease, 2023 Pleural effusion is a rare complication of lymphoplasmacytic lymphoma. When it occurs, traditional investigation techniques may not always be successful.
Emanuele Stirpe +2 more
doaj +1 more source
British Journal of Haematology, 2020 Data on cause‐specific mortality after lymphoplasmacytic lymphoma (LPL) and Waldenström macroglobulinaemia (WM) are lacking. We identified causes of death amongst 7289 adults diagnosed with incident first primary LPL (n = 3108) or WM (n = 4181) during ...
N. Dalal +4 more
semanticscholar +1 more source
Clinical Case Reports, 2021 Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood.
Mizba Baksh +8 more
doaj +1 more source
Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia
Nature Communications, 2018 Waldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is a non-Hodgkin-type B cell lymphoma. Here, the authors identify two risk loci for WM/LPL in a two-stage GWAS involving a family-oversampling approach and provide evidence for a ...
Mary L. McMaster +80 more
doaj +1 more source
Granulomatous Panniculitis in a Patient Treated With Cemiplimab: Case Report and Literature Review
JEADV Clinical Practice, Volume 5, Issue 2, Page 664-668, June 2026.ABSTRACT Immune checkpoint inhibitors (ICIs) have become a cornerstone in the treatment of advanced malignancies by enhancing antitumor immunity, but they may also trigger a broad spectrum of immune‐related adverse events (irAEs) involving multiple organs.
B. Lada‐Colunga +6 more
wiley +1 more source
Lymphoplasmacytic Lymphoma and Waldenström Macroglobulinemia
Archives of Pathology & Laboratory Medicine, 2013 Lymphoplasmacytic lymphoma (LPL) is a low-grade, B-cell neoplasm composed of small lymphocytes, plasmacytoid lymphocytes, and plasma cells that typically involve the bone marrow, and it is associated with an immunoglobulin M (IgM) gammopathy. The definition of Waldenström macroglobulinemia (WM) and its relationship to LPL has been confusing in the past.
Nadia, Naderi, David T, Yang
openaire +2 more sources
British Journal of Haematology, EarlyView.Renal dysfunction represents a possible underrecognized complication of symptomatic WM; this condition correlates with adverse global and disease‐specific clinical outcomes. Summary The prognostic significance of impaired renal function in Waldenström macroglobulinaemia (WM) remains poorly defined.
Nicolò Danesin +27 more
wiley +1 more source
British Journal of Haematology, EarlyView.Optical genome mapping (OGM) is feasible on fresh and frozen tissue lymphoma samples and demonstrated its added value for accurate diagnostic classification. OGM surpasses karyotype and FISH in refining diagnoses of lymphoma, identifying class‐defining rearrangements along with prognostic markers.
Coura Fall +15 more
wiley +1 more source
Case Reports in Hematology, 2016 Waldenstrom’s macroglobulinaemia is the most commonly reported subtype of lymphoplasmacytic lymphoma (LPL); it is characterised by IgM secretion. Neurological complications are common usually as a result of hyperviscosity.
Daniel Halperin +4 more
doaj +1 more source